Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • By Topic
    • Issue Archive
    • Scientific Sessions Abstracts
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Journal Policies
    • Instructions for Authors
    • Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • By Topic
    • Issue Archive
    • Scientific Sessions Abstracts
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Journal Policies
    • Instructions for Authors
    • Peer Review
Commentary

How Sweet It Is: Intestinal Sweet Taste Receptors in Type 2 Diabetes

  1. Jerry R. Greenfield and
  2. Donald J. Chisholm⇑
  1. Garvan Institute of Medical Research, Sydney, Australia.
  1. Corresponding author: Donald J. Chisholm, d.chisholm{at}garvan.org.au.
Diabetes 2013 Oct; 62(10): 3336-3337. https://doi.org/10.2337/db13-1018
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

In humans, there are a number of taste receptors on the tongue. These include G protein–coupled receptors (GPRs) for sweet, bitter, and umami (savory) tastes and ion channel–based receptors for salt and sour. In recent years, there has been increasing interest in the distribution and function of these receptors elsewhere in the body (1). This has led to interesting and occasionally surprising findings, some with potential therapeutic implications (e.g., activation of bitter taste receptors in the airway’s smooth muscle causes bronchodilation, suggesting a novel target for asthma therapy) (2). Of particular interest in the area of diabetes and obesity is the role of sweet taste receptors (STRs) in the intestine (3,4).

The upper gastrointestinal tract is well-endowed with taste and fat receptors, with sweet taste being detected, as elsewhere, by a heterodimer of the taste 1 receptor (T1R) family, T1R2/T1R3. These receptors have been localized to intestinal brush and enteroendocrine cells, and are coupled with α-gustducin as the α-subunit of the G protein (Fig. 1). They recognize sugars, d-amino acids, sweet proteins, and artificial sweeteners. Of importance to a possible role in the incretin response, these receptors are colocalized with glucagon-like peptide 1 (GLP-1) and L cells containing peptide YY (PYY) and K cells containing glucose-dependent insulinotropic polypeptide (GIP) (3). Incidentally, fatty acid responsive GPRs are also coupled to GLP-1 release, but are found predominantly in the colon (5).

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Putative relationships between intestinal STRs, SGLT1 and GLUT2, glucose absorption, and incretin hormones GLP-1, GIP, and PYY.

The ability of intestinal STRs to activate the incretin response in humans without transport of sugars through the intestinal wall is not entirely clear. In vitro, nonnutritive sweeteners can release GLP-1 from L or GLUTag cells, a GLP-1–secreting cell line. Mice deficient in T1R3 or α-gustducin have reduced GLP-1 release in response to glucose (6), and lactisole, an STR blocker, reduces GLP-1 and PYY secretion and increases the glycemic response to intraduodenal (ID) or intragastric glucose in humans (7,8). On the other hand, the glucose transporters SGLT1 (luminal) and GLUT2 (apical, regarded as not rate limiting) are clearly important for incretin hormone release, and SGLT1-deficient mice have a loss of incretin responsiveness (9). In humans, there is equivocal evidence for an STR-mediated incretin response. Intragastric sucralose failed to stimulate GLP-1 or GIP release (10), but prior ingestion of sucralose-containing diet soda accentuated the GLP-1 response to oral glucose without significantly affecting insulin levels (11). It seems the role of the STRs may, in part, be to upregulate intestinal SGLT1, as this important intestinal transporter is increased by luminal sweeteners in normal, but not T1R3 or α-gustducin deficient, mice (12).

In this issue, Young et al. (13) add to what they and others have previously shown regarding STRs in type 2 diabetes. Prior evidence indicates that intestinal SGLT1 levels may be increased in type 2 diabetes and glucose transport in duodenal biopsies may be enhanced (14). Duodenal expression of STRs in the fasting state did not differ between diabetic and control subjects, but it was inversely related to glycemia in diabetic subjects (15). In rodents, intestinal STRs are rapidly downregulated by luminal glucose or nonnutritive sweeteners (16). In the new report, type 2 diabetic and control subjects were studied at euglycemia and hyperglycemia with a 30-min ID infusion of glucose containing 3-O-methyl-glucose (3-OMG) to assess glucose absorption. Duodenal biopsies were taken before and after the infusion. Basal intestinal mRNA copy number was substantially different for TRPM5 > α GD > TIR3 > TIR2, but did not differ between diabetic and control subjects. Further, 10–20% of TIR2 cells coexpressed GLP-1 or GIP, and hyperglycemia did not affect TIR2 levels in either group. However, ID glucose increased TIR2 in both groups at euglycemia, but at hyperglycemia, TIR2 was lower in control subjects but higher in diabetic subjects. Moreover, 3-OMG levels were significantly elevated at hyperglycemia in diabetic versus control subjects, but only at 60 min after initiation of ID glucose. The area under the curve for 3-OMG was greater with hyperglycemia, but not different between groups, an observation that may relate to competition for clearance between 3-OMG and glucose. Young et al. suggest the increased 60-min 3-OMG level was likely due to upregulation of SGLT1 (which was not directly measured in the study) by TIR2-related mechanisms. If correct, this would suggest that the STR response may act to enhance the relative rate of glucose absorption and accentuate postprandial hyperglycemia in type 2 diabetes.

It should be mentioned that there was, not unexpectedly, considerable variability in the STR component measurements. Thus, while the difference in the TIR2 response to ID glucose between diabetic and control subjects at hyperglycemia is convincing, other changes in STR components in response to ID glucose may have failed to reach statistical significance because of the relatively large variability in these measures.

Another salient point in this study relates to the incretin hormones GLP-1 and GIP, whose secretion in response to ID glucose corresponded with STR transcript levels. This was consistent with the previously mentioned role of the STRs in regulation of the incretin hormones. Interestingly, GLP-1 and GIP levels in diabetic subjects in response to ID glucose were as great or greater than control subjects, which contrasts with (inconsistent) previous data suggesting reduced GLP-1 secretion in type 2 diabetes (17,18). Young et al. suggest that the GLP-1 response to oral glucose in type 2 diabetes may be affected by well-described variability and delay in gastric emptying among these patients, whereas in this study the glucose was directly delivered to the intestine.

What are the implications of these and prior results? First, they are consistent with, but do not absolutely prove, an influence of intestinal STRs on incretin hormones in humans, thereby suggesting another possible route for pharmacological enhancement of the incretin response. Second, these findings suggest an unfavorable impact of disturbed STR regulation in type 2 diabetes—enhancement of glucose absorption during hyperglycemia, which could accentuate postprandial hyperglycemia and lessen the benefit of energy reduction from nonnutritive sweeteners. This raises the question as to whether these disturbances might occur in the prediabetic state. Although intake of low-calorie drinks might be expected to lessen adiposity and the risk of type 2 diabetes, it has nonetheless been associated epidemiologically with increased diabetes risk (19). Could the nonnutritive sweeteners in these drinks be accentuating postprandial glycemia via effects on STRs, thereby contributing to the progression of glucose intolerance?

Young et al. (13) add an extra chapter in the developing story of intestinal taste receptors, which clearly has a long way to go.

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying original article, p. 3532.

  • © 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

  1. ↵
    1. Yamamoto K,
    2. Ishimaru Y
    . Oral and extra-oral taste perception. Semin Cell Dev Biol 2013;24:240–246pmid:22963927
    OpenUrlCrossRefPubMed
  2. ↵
    1. Zhang CH,
    2. Lifshitz LM,
    3. Uy KF,
    4. Ikebe M,
    5. Fogarty KE,
    6. ZhuGe R
    . The cellular and molecular basis of bitter tastant-induced bronchodilation. PLoS Biol 2013;11:e1001501pmid:23472053
    OpenUrlCrossRefPubMed
  3. ↵
    1. Janssen S,
    2. Depoortere I
    . Nutrient sensing in the gut: new roads to therapeutics? Trends Endocrinol Metab 2013;24:92–100pmid:23266105
    OpenUrlCrossRefPubMed
  4. ↵
    1. Young RL
    . Sensing via intestinal sweet taste pathways. Front Neurosci 2011;5:23pmid:21519398
    OpenUrlPubMed
  5. ↵
    1. Li Y,
    2. Kokrashvili Z,
    3. Mosinger B,
    4. Margolskee RF
    . Gustducin couples fatty acid receptors to GLP-1 release in colon. Am J Physiol Endocrinol Metab 2013;304:E651–E660pmid:23341498
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Jang HJ,
    2. Kokrashvili Z,
    3. Theodorakis MJ,
    4. et al
    . Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 2007;104:15069–15074pmid:17724330
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Steinert RE,
    2. Gerspach AC,
    3. Gutmann H,
    4. Asarian L,
    5. Drewe J,
    6. Beglinger C
    . The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Clin Nutr 2011;30:524–532pmid:21324568
    OpenUrlCrossRefPubMed
  8. ↵
    1. Gerspach AC,
    2. Steinert RE,
    3. Schönenberger L,
    4. Graber-Maier A,
    5. Beglinger C
    . The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans. Am J Physiol Endocrinol Metab 2011;301:E317–E325pmid:21540445
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Gorboulev V,
    2. Schürmann A,
    3. Vallon V,
    4. et al
    . Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012;61:187–196pmid:22124465
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Ma J,
    2. Bellon M,
    3. Wishart JM,
    4. et al
    . Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. Am J Physiol Gastrointest Liver Physiol 2009;296:G735–G739pmid:19221011
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Brown RJ,
    2. Walter M,
    3. Rother KI
    . Ingestion of diet soda before a glucose load augments glucagon-like peptide-1 secretion. Diabetes Care 2009;32:2184–2186pmid:19808921
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Margolskee RF,
    2. Dyer J,
    3. Kokrashvili Z,
    4. et al
    . T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA 2007;104:15075–15080pmid:17724332
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Young RL,
    2. Chia B,
    3. Isaacs NJ,
    4. et al
    . Disordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes. Diabetes 2013;62:3532–3541pmid:23761104
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Dyer J,
    2. Wood IS,
    3. Palejwala A,
    4. Ellis A,
    5. Shirazi-Beechey SP
    . Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol 2002;282:G241–G248pmid:11804845
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Young RL,
    2. Sutherland K,
    3. Pezos N,
    4. et al
    . Expression of taste molecules in the upper gastrointestinal tract in humans with and without type 2 diabetes. Gut 2009;58:337–346pmid:19039089
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Mace OJ,
    2. Affleck J,
    3. Patel N,
    4. Kellett GL
    . Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT2. J Physiol 2007;582:379–392pmid:17495045
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Toft-Nielsen MB,
    2. Damholt MB,
    3. Madsbad S,
    4. et al
    . Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717–3723pmid:11502801
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Vollmer K,
    2. Holst JJ,
    3. Baller B,
    4. et al
    . Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678–687pmid:18057091
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Fagherazzi G,
    2. Vilier A,
    3. Saes Sartorelli D,
    4. Lajous M,
    5. Balkau B,
    6. Clavel-Chapelon F
    . Consumption of artificially and sugar-sweetened beverages and incident type 2 diabetes in the Etude Epidemiologique aupres des femmes de la Mutuelle Generale de l’Education Nationale-European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr 2013;97:517–523pmid:23364017
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes: 62 (10)

In this Issue

October 2013, 62(10)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How Sweet It Is: Intestinal Sweet Taste Receptors in Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
Citation Tools
How Sweet It Is: Intestinal Sweet Taste Receptors in Type 2 Diabetes
Jerry R. Greenfield, Donald J. Chisholm
Diabetes Oct 2013, 62 (10) 3336-3337; DOI: 10.2337/db13-1018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

How Sweet It Is: Intestinal Sweet Taste Receptors in Type 2 Diabetes
Jerry R. Greenfield, Donald J. Chisholm
Diabetes Oct 2013, 62 (10) 3336-3337; DOI: 10.2337/db13-1018
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • “NO” to Autophagy: Fat Does the Trick for Diabetes
  • SCP4: A Small Nuclear Phosphatase Having a Big Effect on FoxOs in Gluconeogenesis
  • Ambient Air Pollution and Type 2 Diabetes: Do the Metabolic Effects of Air Pollution Start Early in Life?
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • For Advertisers
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2018 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.